GSK, Novartis complete billions of dollars in deals
GlaxoSmithKline (NYSE:GSK) and Novartis (NYSE:NVS) have completed a series of asset swaps worth more than $20B that will reshape both drugmakers. Glaxo is forming a consumer health joint venture with Novartis, while at the same time buying the Swiss company's vaccines business and divesting its cancer drugs portfolio to Novartis. Following completion of the transactions, Glaxo plans to return £4B ($6.16B) to shareholders.